Pemetrexed in the treatment of advanced non-small-cell lung cancer: A review of the clinical data

Clinical Lung Cancer

Volumn 5, Issue SUPPL. 2, 2004, Pages

  Zinner, Ralph G ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Combination therapy; Platinum agents; Single agent therapy; Tolerability; Toxicity; Vitamin supplementation

Indexed keywords

ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; FOLIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RADIOSENSITIZING AGENT;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; REVIEW; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 2342609857     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.s.006     Document Type: Article

References (48)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Surveillance, Epidemiology, and End Results Program, 1973-1999. Bethesda, MD: Division of Cancer Control and Population Sciences, National Cancer Institute, 2002.
3. Non-small cell lung cancer collaborative group: chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311:899-909.
4. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27:145-157.
5. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:1074-1780.
6. Gridelli C: The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small-cell lung cancer-Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001; 6(suppl 1):4-7.
7. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 2000; 83:447-453.
8. Negoro S, Masuda N, Takada, Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003; 88:335-341.
9. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
10. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Ontology Group study. J Clin Oncol 1998; 16:2459-2465.
11. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:3390-3399.
12. Le Chevalier T, Brisgand D, Soria JC, et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001; 6(suppl 1):8-11.
13. Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16:2133-2141.
14. Belani CP, Natale RB, Lee JS, et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Assoc Cancer Res 1998; 39:256 (Abstract #1751).
15. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17:12-18.
16. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623-631.
17. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Study Group. J Clin Oncol 2004; 22:254-261.
18. Grigorescu AC, Draghici IN, Nitipir C, et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 2002; 37:9-14.
19. Smit EF, Van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21:3909-3917.
20. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291.
21. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multicenter, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX326 study group. J Clin Oncol 2003; 21:3016-3024.
22. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
23. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
24. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
25. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
26. Fukuoka M, Yano S, Giaccone G, et al. Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
27. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
28. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003; 3:145-156.
29. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644.
30. Hanna NH, Shepherd FA, Rosell R, et al. A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 2003; 22:622 (Abstract #2503).
31. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57:1116-1123.
32. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1:545-552.
33. Bunn P, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of Alimta. (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Oncol 2001; 20:76a (Abstract #300).
34. Jackson RC, Fry DW, Boritz K, et al. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul 1984; 22:187-206.
35. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17:1194-1199.
36. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium. (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002; 13:737-741.
37. Smit EF, Mattson K, von Pawel J, et al. Alimta (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003; 14:455-460.
38. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and rharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin J Clin Oncol 1999; 17:3009-3016.
39. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer 2001; 92:595-600.
40. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11:435-440.
41. Zinner R, Obasaju CK, Fossella FV, et al. Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): a phase II trial. Proc Am Soc Clin Oncol 2003; 22:642 (Abstract #2580).
42. Scagliotti G, Kortsik C, Castellano D, et al. Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:625 (Abstract #2513).
43. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20:3533-3544.
44. Monnerat C, LeChevalier T, Novello S, et al. Clinical results from a phase II trial of pemetrexed + gemcitabine in advanced non-small cell lung cancer. Ann Oncol 2002;13 (suppl 5):132 (Abstract #483PD).
45. Clarke S, Underhill C, White S, et al. Phase II study of pemetrexed and vinorelbine in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol 2002; 13(suppl 5):149 (Abstract #546P).
46. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18:1748-1757.
47. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360.
48. Vokes E, Szeto L, Mauer A, et al. A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small-cell lung cancer or esophageal cancer. Lung Cancer 2003; 41(suppl 2):S89 (Abstract #O-89).